Vamifeport (VIT-2763), the first clinical-stage oral FPN inhibitor, binds FPN’s central site, structurally overlapping hepcidin’s interaction site, competitively blocking hepcidin binding, this therapeutic is under clinical evaluation for β-thalassemia and sickle cell disease [123]. Here, SLC40A1 is linked to sickle cell disease.